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Abstract
Acute necrotizing encephalopathy (ANE) is characterized by symmetrical brain necrosis, suggested to be due to
breakdown of the blood–brain barrier (BBB). We experienced a rare case of ANE complicated with systemic lupus
erythematosus (SLE), and found that the patient’s serum (V10-5) had binding activity to human umbilical vein
endothelial cells (HUVECs). By SARF (Serological identification system for Autoantigens using a Retroviral vector and
Flow cytometry) method using V10-5 IgG, a clone bound to V10-5 IgG was isolated. This cell clone was integrated
with cDNA identical to EphB2, which plays critical roles in neuronal cells and endothelial cells. HUVECs and human
brain microvascular endothelial cells expressed EphB2 and the V10-5 IgG bound specifically to EphB2-transfected
cells. Anti-EphB2 antibody was not detected in other SLE patients without ANE. In this report, we identified EphB2
as a novel autoantigen, and anti-EphB2 antibody may define a novel group of brain disorders. Anti-EphB2 antibody
can interfere not only with endothelial cells including those of the BBB (acting as an anti-endothelial cell antibody),
but also neuronal cells (acting as an anti-neuronal antibody) if the BBB has been breached. Future studies should
determine the clinical prevalence and specificity of anti-EphB2 antibody, and the molecular mechanisms by which
anti-EphB2 antibody mediates neuronal and vascular pathological lesions.
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Background
A group of brain disorders involving autoantibodies
targeting cell-surface or synaptic proteins has been identi-
fied. The antigens include N-methyl-D-aspartate receptor
(NMDAR), α-amino-3-hydroxy-5-methyl-4-isoxazolepro-
pionic acid receptor (AMPAR), γ-aminobutyric acid recep-
tor-B (GABAB receptor), leucine-rich glioma-inactivated
protein 1 (LGI1), contactin-associated protein-like 2
(Caspr2), glycine receptor (GlyR), and metabotropic glu-
tamatereceptormGluR5[1].
Autoantibodies cause tissuedamage throughanumberof
mechanisms.Especially,cell-surfacetargetantigensaresus-
ceptible to disruption by autoantibodies, and syndromes
mediated by these autoantibodies often mimic animal
modelswith genetic or pharmacological disruption of these
molecules [1]. Identifying these autoantigens would be
helpful in understanding the pathophysiology of these
syndromes.
Acute necrotizing encephalopathy (ANE) is a rare type of
acuteencephalopathyfirstdescribedinJapan.Thediagnosis
is based on the topographic distribution and evolution of
symmetric lesions visualized by computed tomography
(CT)andmagnetic resonance imaging (MRI) in thebilateral
thalami and other specific brain areas [2]. Although the
pathogenesis remained obscure, vasculopathy with break-
downoftheblood–brainbarrier(BBB)wassuggested[3].
Recently, we established a novel method to identify cell-
surface autoantigens, which we named Serological identi-
fication system for Autoantigens using a Retroviral vector
and Flow cytometry (SARF) [4,5].Using SARF,we success-
fully identified ephrin type B receptor 2 (EphB2), which
has critical functions in neuronal and endothelial cells
(ECs) [6], as a target of autoantibody from a patient with
ANE complicated with systemic lupus erythematosus
(SLE).
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Methods
Source of human serum
Forty-eight patients with SLE (44 female and 4 male pa-
tients) diagnosed according to the 1997 revised criteria
for the classification [7] were enrolled in this study. The
patients gave written consent after the purpose and po-
tential risks involved in the study were explained. The
study protocol complied with the principles of the Dec-
laration of Helsinki and was approved by the Ethics
Committee of Tohoku University Graduate School of
Medicine.
Cell culture
Human umbilical vein ECs (HUVECs), Plat-E packaging
cells, rat myeloma cells: YB2/0, and medium were pur-
chased and grown as described previously [4]. Human
brain microvascular ECs (HBMECs) and medium were
purchased from Cell Systems (Kirkland, WA, USA).
Flow cytometry
Binding activities of antibodies to the surface of ECs and
EphB2weremeasuredandanalyzedasdescribedpreviously
[4]. Briefly, aliquots of 1 × 105 cells/tube were incubated in
blocking buffer with primary antibodies at 4°C for 30 mi-
nutes. After washing, cells were incubated with secondary
antibodies and 7-amino-actinomycin D (7-AAD) (BD
Biosciences, Bedford, MA, USA) at 4°C for 30 minutes and
analyzedbyflowcytometry.
Goat anti-human EphB2 antibody was purchased from
R&D Systems (Minneapolis, MN, USA), and recombin-
ant EphB2 was purchased from Sino Biological (Beijing,
China).
SARF
Generation of HUVEC cDNA library and screening of
cDNA were performed as described previously [4]. Briefly,
the HUVEC cDNA library was retrovirally transfected into
the YB2/0 cells. YB2/0 cells expressing the HUVEC cDNA
library were incubated with serum IgG and fluorescein
isothiocyanate (FITC)-labeled secondary antibody. Cells
showing a high level of FITC fluorescence were sorted
with FACSAriaII (Becton Dickinson, Franklin Lakes, NJ,
USA). Sorted cells were kept in culture until the cell num-
ber increased sufficiently for the next round of sorting.
Subcloning of cells was performed by the limiting dilution
method. Total RNAs of cloned cells and unsorted cells
were generated and subjected to microarray analysis
(GeneChip Human Genome U133 Plus 2.0 Array;
Affymetrix, Santa Clara, CA, USA).
Expression of EphB2 in YB2/0 cells
The full-length EphB2 fragment was amplified by PCR
from genomic DNA of EphB2-expressing YB2/0 clone
sorted as described above, using Phusion High-Fidelity
DNA Polymerase (Finnzymes, Keilaranta, Espoo, Finland).
Primer sequences were as follows: 5′-AAGCGCAGC
CATGGCTCT-3′, 3′-AGGCAGGTGAATGTCAAACC-
5′. EphB2 fragment was inserted into the pMX-IRES-GFP
vector (Cell Biolabs, San Diego, CA, USA).
Case presentation
Case of ANE complicated with SLE
A 39-year-old Japanese woman was admitted to our hos-
pital because of coma. One day previously, she had been
admitted to another hospital because of diarrhea lasting
three days. The next morning, she suddenly fell into a
coma and developed quadriplegia, and was transferred to
our hospital. On admission, her consciousness was
GCSE1V1M2, both pupil sizes were 3 mm, and both
pupillary light reflexes were absent. Decorticate rigidity
and Babinski reflex were present. The cerebrospinal fluid
(CSF) showed normal glucose and no pleocytosis, but the
total protein level was elevated to 316 mg/dL. Laboratory
tests indicated lymphopenia (410/μL), and elevated levels
of aspartate aminotransferase (AST; 136 IU/L), lactate de-
hydrogenase (LDH; 740 IU/L), and C-reactive protein
(CRP; 0.9 mg/dL). Serum complement levels were de-
creased as follows: C3, 42 mg/dL; C4, 5.3 mg/dL CH50,
10.8 U/mL. Antinuclear antibody (ANA) (×640, speckled)
and anti-Sm antibody (48.7 index) were positive, but anti-
dsDNA antibody and anti-phospholipid antibodies were
negative. Tests for infections and urine were negative. CT
showed low density area in the bilateral thalami, basal
ganglia, medial temporal lobe, and brainstem (Figure 1A).
MRI revealed high signal intensity in T2 (Figure 1B) and
diffusion-weighted images in the same areas as described
above (Figure 1C). A diagnosis of neuropsychiatric SLE
(NPSLE) manifesting ANE was made based on the clinical,
serological, and imaging findings. Despite extensive treat-
ment, her consciousness did not recover, and she
remained in a permanently vegetative state.
Identification of EphB2 as a novel cell-surface
autoantigen
Serum from this patient (V10-5) showed strong binding
activity to HUVECs (anti-endothelial cell antibody (AECA)
activity) (Figure 2A). Using SARF, the YB2/0 cell line ex-
pressing HUVEC cDNA was incubated with V10-5 IgG
and FITC-conjugated secondary antibody, and cells with
strong FITC signals were sorted by flow cytometry
(Figure 2B). After cell expansion, we repeated three more
rounds of cell sorting. After the fourth round of sorting,
cells bound to V10-5 IgG were markedly increased
(Figure 2C, upper). Then, one clone (C17) was established
from the V10-5 IgG-binding cell population by the limiting
dilution method (Figure 2C. lower).
Microarray analysis of unsorted YB-2/0 and C17 indi-
cated that the signal of EphB2 was significantly increased
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(26.16-fold) in C17 compared to unsorted cells, and we con-
firmed that the EphB2 cDNAwas inserted into the genomic
DNA of the V10-5-C17 clone by PCR (Figure 2D). We also
confirmed the expression of EphB2 on theV10-5-C17 clone
by flow cytometry (Figure 2E). Next, we generated an ex-
pression vector for EphB2, which was transfected into
YB2/0 cells. V10-5 IgG showed significant binding activity
to EphB2-expressing YB2/0 cells (Figure 2F), indicating that
V10-5 IgG has anti-EphB2 activity. Thus, EphB2 was
identified as a novel autoantigen in a patient with ANE
complicatedwith SLE.
Flow cytometry indicated that HUVECs and HBMECs
also expressed EphB2 on their cell surfaces (Figure 3A).
We conducted inhibition tests to determine whether the
AECA activity of V10-5 IgG was due to anti-EphB2 activ-
ity. Anti-HBMEC activity of V10-5 IgG was inhibited by
addition of recombinant EphB2 (Figure 3B). We also ana-
lyzed the IgG subclasses of anti-EphB2 antibody by flow
Figure 1 Clinical imaging. (A) CT showed low density area in the bilateral thalami, basal ganglia, medial temporal lobe, and brainstem. The
brainstem was swollen, and high density area was observed in the pons. (B) MRI (T2-weighted image) revealed high signal intensity in the
bilateral thalami, basal ganglia, medial temporal lobe, and brainstem. (C) MRI (diffusion-weighted image) also showed high signal intensity in the
same area.
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cytometry. IgGs with anti-EphB2 activity were IgG1, IgG2,
and IgG3 (Figure 3C).
Although we measured anti-EphB2 activity among 47
SLE patients (nine patients had been diagnosed with
NPSLE, none of them presented ANE) who had AECA
activities, anti-EphB2 antibody was not detected in any
other SLE patients examined.
Discussion
Identification of EphB2 as a novel autoantigen may be
important in clarifying the pathogenesis of ANE because
anti-EphB2 antibody has potential to play pathogenic
roles in neuronal and vascular lesions.
ANE has a high mortality rate and is usually preceded
by infections, such as influenza, with the signs of brain
dysfunction appearing a few days later [8]. It is charac-
terized by symmetrical brain necrosis, which involves
the thalamus followed by the tegmentum of the pons
and other regions, and these are demonstrated by CT
and MRI [3]. Neuropathologically, the lesions tend to
spread along small blood vessels, and the extent of the
lesions appears to be determined by the spread of edema
fluid. These observations indicate the vasogenic nature
Figure 2 Identification of ephrin type B receptor 2 (EphB2) as a novel autoantigen. (A) Nonpermeabilized human umbilical vein
endothelial cells (HUVECs) were stained with 0.5 mg/mL of IgG of control or V10-5 followed by secondary antibody and analyzed by flow
cytometry. (B) HUVEC cDNA-expressing cells were stained with 0.5 mg/mL of V10-5 IgG followed by secondary antibody, and cells in the positive
fraction were sorted (squares). (C) Unsorted cells and those at the fourth round of sorting (upper), and unsorted and cloned cells from those at
the fourth round of sorting, C17 (lower), were stained with 0.5 mg/mL of V10-5 IgG followed by secondary antibody, and analyzed by flow
cytometry. (D) EphB2 cDNA fragments inserted into the genomic DNA of C17 were amplified, and PCR products were electrophoresed on a 0.8 %
agarose gel. (E) Unsorted and C17 were stained with isotype control or anti-EphB2 antibody, followed by secondary antibody and analyzed by
flow cytometry. (F) Expression vector, empty-IRES-GFP, or EphB2-IRES-GFP was transfected into YB 2/0 cells, and the cells were stained with
0.5 mg/mL of control IgG or V10-5 IgG, followed by secondary antibody and analyzed by flow cytometry.
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Figure 3 Confirmation of anti-EphB2 activity of V10-5 IgG. (A) Nonpermeabilized human umbilical vein endothelial cells (HUVECs) and
human brain microvascular cells (HBMECs) were stained with isotype control or anti-EphB2 antibody followed by secondary antibody, and
analyzed by flow cytometry. (B) Inhibition tests of binding activities to HBMECs were performed using V10-5 IgG with soluble EphB2 at the
indicated concentrations. Control indicates binding activity of IgG from healthy donor to HBMECs. (C) EphB2-expressing or non-expressing YB2/0
cells were stained with 1:10 diluted V10-5 serum followed by secondary antibody against human IgG1, IgG2, IgG3, IgG4, or IgM, and analyzed by
flow cytometry.
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of edema-necrosis in ANE, resulting from local break-
down of the BBB [8]. EC necrosis and inflammatory fi-
brinoid vasculitis have also been reported [9].
Although our patient showed characteristic features of
ANE, this is a very rare complication of SLE; to our know-
ledge, no other cases of SLE manifesting ANE have been
reported to date. Although some previous reports indi-
cated the absence of ANA in ANE [2], the correlation be-
tween SLE and ANE is uncertain.
Eph receptors belong to one of the largest families of
tyrosine kinases. They are known to have diverse func-
tions in neural development, cell morphogenesis, tissue
patterning, angiogenesis, and neural plasticity [6]. Among
them, the critical roles of EphB2 in the nervous system
have recently been clarified. The important functions of
EphB2 include regulation of NMDAR-dependent Ca2+ in-
flux and downstream transcription factors in neuronal
cells [10], and the involvement in neurological diseases,
including Alzheimer’s disease, anxiety, and anti-NMDA
encephalitis has been reported [11-13]. We performed an
immunohistochemical study of mouse brain tissues using
a commercially available anti-EphB2 antibody. As a result,
we identified positive reactions on neural cells and glia in
the cerebral cortex and also ECs in the subarachnoid re-
gions (data not shown). Further studies would be done to
investigate whether the reactivity of the patient’s anti-
bodies with brain is abrogated by immunoadsorption with
EphB2 or in EphB2 knockout mice tissues. Interestingly,
EphB2 is also expressed on ECs and is required for EC for-
mation of cord-like structures [14].
Thus, anti-EphB2 antibody could potentially interfere
not only with ECs including those of the BBB (acting as
an AECA), but also neuronal cells (acting as an anti-
neuronal antibody) if the BBB has been breached. Taken
together, the possible suspected pathomechanisms are 1)
anti-EphB2 antibody damages vascular ECs, which results
in breakdown and increased permeability of BBB; 2) anti-
EphB2 antibody exudated into brain tissue binds neurons
and glia, which causes neuronal dysfunction and brain
necrosis.
In the present study, anti-EphB2 antibody was not
detected in any other patients with SLE, none of whom
manifested ANE. Although we did not evaluate the preva-
lence of anti-EphB2 antibody in other ANE patients be-
cause of its rarity, anti-EphB2 antibody may define a novel
group of brain disorders the clinical manifestations of
which are similar to those of ANE. If this is the case, anti-
EphB2 antibody may be a useful biomarker, and provide
new insight into such brain disorders.
Conclusion
We identified EphB2 as a novel autoantigen in a patient
with ANE complicated with SLE. Anti-EphB2 antibody
may have dual activity as an AECA and an anti-neuronal
antibody. Further studies are needed to determine the
clinical prevalence and specificity of anti-EphB2 antibody,
and the molecular mechanisms by which anti-EphB2 anti-
body mediates neuronal and vascular pathological lesions.
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